ATLAS Trial of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years for Early Breast Cancer


ATLAS Trial of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years for Early Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from recent interviews with Sir Richard Peto (1/11/13) and Rowan T Chlebowski, MD, PhD (1/9/13)
Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012;[Epub ahead of print]. Abstract

Dr Chlebowski is Professor of Medicine at David Geffen School of Medicine at UCLA and Chief of the Division of Medical Oncology and Hematology at Harbor-UCLA Medical Center in Torrance, California.

Sir Richard Peto is Professor of Medical Statistics and Co-director of the Clinical Trial Service Unit at the University of Oxford in Oxford, United Kingdom.